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The persistence of a viral reservoir in HIV-1 infected patients
under suppressive antiviral treatment has thus far prevented achiev-
ing a functional HIV-1 cure. Crucial in these initial strides to identify
cure strategies is patient selection. Interventional research on cure in
HIV-1 patients usually aims to demonstrate at least one of the follow-
ing outcomes: a significant depletion of the inducible viral reservoir
or the stable absence of renewed viral replication as the infected
patient discontinues antiviral therapy. In this article of EBioMedicine,
Galvez et al. [1] identify a unique “LoViRet” patient category with an
exceptionally low viral reservoir under c-ART, despite starting ther-
apy during the chronic phase of the disease. So how do the different
parameters to assess the success of investigational HIV-1 cure strate-
gies apply to LoViRet patients and how can we harness these insights
into meaningful interventional studies?
First, the presence of a small inducible latent viral reservoir that
can be therapeutically targeted, as present in LoViRet patients, is
likely essential for current pilot studies that aim to demonstrate the
possibility of an antiretroviral drug-free life in patients with chronic
HIV-1 infections. One of the promising strategies studied over the
last decade to achieve HIV-1 cure addresses the caveat that latent
HIV-infected cells remain invisible to antiviral host responses. By
pharmacologically triggering HIV-1 gene expression through so-
called latency reversing agents (LRA), we can reverse latency [2,9].
Hope is then put on elimination of reactivated cells via (drug-
boosted) viral cytopathic or intrinsic host cell pro-apoptotic mecha-
nisms or via extracellular immune effector cell-based clearance [3,9].
Hence, the presence of a small limited reservoir in LoViRet patients is
likely beneficial to achieve significant reservoir elimination via cura-
tive intervention strategies.
Secondly, a competent immune compartment is key to eliminate
residual reservoir cells. Because chronically infected individuals gen-
erally present an impaired immune compartment, harnessing potentDOI of original article: http://dx.doi.org/10.1016/j.ebiom.2020.102830.
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cation trials. Thus, to achieve efficient elimination of HIV-1 infected
cells, latency reversal would ideally be combined with approaches
that effectively trigger mechanisms of killing by enhancing extrinsic
immune-based clearance or inducing intrinsic cell death [4,5].
LoViRet patients described by Galvez et al., while chronically HIV-1
infected, have a remarkably low viral reservoir together with an over-
all preserved immune compartment. Notably, these exceptional char-
acteristics are generally found in HIV-1 controllers and patients who
initiate c-ART in the acute stage of the infection [6,7]. Galvez et al.
observed a direct correlation between low HIV-1 DNA levels in
LoViRet individuals and a preserved CD8+ T cell compartment before
treatment and higher proportion of naïve CD8+ T cells after treatment
initiation. Such traits hint towards a less impaired immune system
and likely better cytotoxic responses before and after c-ART, that
could potentially prevent a massive reservoir seeding. In context of
reservoir depletion studies that center on viral reactivation and clear-
ance, selection of patient cohorts with not only a lower reservoir
threshold but also an intrinsically preserved cytotoxic cellular immu-
nity compartment is thus likely crucial to reach an effective elimina-
tion of HIV-1 infected cells.
Another striking observation, described by Galvez et al., is that
CD8+ T cells from LoViRet individuals do not show enhanced anti-
viral inhibition activity or a less immune exhausted phenotype
when compared to controls, despite having low levels of circulat-
ing HIV-1 antigen. This seems to be different from CD8+ T cells
from HIV controllers [6] and hints towards a different mechanism
driving the low reservoir size observed in LoViRet. Assessing the
relevance of the specific CD8+ T cell diversity and functionality in
these patients is crucial to infer causality and, because the immune
system is certainly not the only factor influencing reservoir size,
further investigation into the intrinsic host factors (e.g. neutraliz-
ing antibodies, restriction factors or antibody-dependent cellular
cytotoxicity) and viral characteristics is needed to unveil the
mechanisms behind the specific reservoir dynamics observed in
LoViRet individuals.
Thus, additional characterization and insights into the kinetics of
the inducible reservoir in this patient population is needed to put in
perspective a potential role for LoViRet patients in reservoir eradica-
tion studies. Here, future studies will have to deal with assay sensitiv-
ity issues necessitating high input numbers of cells, which limits
applicability. In smaller reservoirs, it will be increasingly difficult to
detect relevant reservoir decay during interventional studies, or to
determine the point at which c-ART can be safely stopped. Also ofr the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
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specificity and avidity of cytotoxic responses is essential to ensure
an efficient elimination of reactivated cells [8]. Lastly, it is important
to note that the far majority of people are diagnosed and treated
during chronic phases of HIV-1. Of these, only a small minority will
hold a LoViRet phenotype, estimated at 6% based on the current
paper. Although non-LoViRet patients have a more unfavorable
starting position in terms of reservoir size, the effect of any inter-
vention on the inducible reservoir decay and its predictive bio-
markers can be better studied. On the other hand, the distinguished
immune features of LoViRet individuals and their correlation to res-
ervoir dynamics accentuate their added value for customized
patient cohorts in HIV-1 cure studies. Patient stratification by
LoViRet state could therefore be very beneficial and serve both
aspects of cure research: optimal reservoir decay study together
with obtaining a functional cure.
All in all, the study presented by Galvez et al. investigates for the
first time the reservoir dynamics and immune characteristics of
chronic patients with a very low level of HIV-1 DNA. Although the
relevance of this cohort in future cure studies is yet to be assessed,
the heterogeneity of HIV-1 patients who started c-ART during chronic
infection supports using stratification by LoViRet status to identify
patients in whom curative interventions is most realistic towards a c-
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